Jun 10, 2020
F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
Feb 27, 2020
Medicinal Genomics Announces New PathoSEEK® Aspergillus Multiplex Assay to Streamline Cannabis Testing
Jan 30, 2020
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
Sep 16, 2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
Sep 09, 2019
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
Jun 07, 2018
Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
Apr 23, 2018
SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
Mar 19, 2018
Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
Feb 01, 2018
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
Jan 24, 2018
Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018
Jan 08, 2018
Amplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference
Oct 09, 2017
Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017
Sep 05, 2017
Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections
Aug 02, 2017
Amplyx Pharmaceuticals Raises $67 Million in Series C Financing
May 30, 2017
Aspergillosis Pipeline Market Global Analysis and Therapeutics Development H1 2017 Report now Available at RnRMarketResearch.com